Solid tumors often exhibit EZH2 overexpression, as reported in various cancer types, with adverse outcomes, including prostate cancer, breast cancer, endometrial cancer, colorectal cancer, melanoma, cholangiocarcinoma, and ovarian cancer. Here, EZH2 is linked to ovarian cancer.